Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial

Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial

<p>Abstract</p> <p>Background</p> <p>Naltrexone is an effective medication for treatment of alcohol dependence, but its efficacy is limited by lack of adherence to the oral dosage form. A long-acting depot formulation of naltrexone may increase adherence.</p> <...

Full description

Bibliographic Details
Main Authors:	Koch Monika, Galloway Gantt P, Cello Ryan, Smith David E
Format:	Article
Language:	English
Published:	BMC 2005-04-01
Series:	BMC Psychiatry
Online Access:	http://www.biomedcentral.com/1471-244X/5/18

Similar Items

Open Label Trial of Naltrexone Implants: Measuring Blood Serum Levels of Naltrexone
by: Ross M. Colquhoun
Published: (2013-05-01)

Open Label Trial of Naltrexone Implants: Measuring Blood Serum Levels of Naltrexone
by: Ross M. Colquhoun
Published: (2013-01-01)

Open-label pilot study of injectable naltrexone for cannabis dependence
by: Brooks, D.J, et al.
Published: (2018)

Low Dose Naltrexone - Efficacy and safety of off-label use therapy.
by: Andrzej Stańczak
Published: (2020-01-01)

Open-Label Study of the Safety and Pharmacokinetics of Solifenacin in Subjects With Hepatic Impairment
by: Mirjam Kuipers, et al.
Published: (2006-01-01)

Effectiveness of Naltrexone Combined with Psychotherapy in the Relapse Prevention of Alcohol Dependence
by: Chao-Hsiang Hsieh, et al.
Published: (2006)

Effects of naltrexone and cross-tolerance to morphine in a learned helplessness paradigm
by: N.A. Teixeira, et al.
Published: (1997-06-01)

Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study
by: Ruoxi Hong, et al.
Published: (2021-02-01)

A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
by: van Rossem K, et al.
Published: (2013-01-01)

A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
by: Ian Mcgowan, et al.
Published: (2015-01-01)

Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review
by: Negin Farhadian, et al.
Published: (2020-03-01)

The effects of Naltrexone among alcohol non-abstainers: results from the COMBINE Study
by: Lara Ray, et al.
Published: (2010-10-01)

Pharmacokinetics of naltrexone and its conjugated metabolites in dogs and rabbits : a study of biliary excretion and enterohepatic recycling /
by: Liao, Sam Hui-tseh
Published: (1979)

Design of a depot formulation for disulfiram
by: Mia, Fatema
Published: (2017)

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study
by: Hans Klose, et al.
Published: (2021-02-01)

ROLE OF LEUPRORELINE ACETATE DEPOT (LUCRIN DEPOT®) FORMULATIONS IN THE TREATMENT OF PROSTATE CANCER
by: M. I. Volkova
Published: (2014-07-01)

ROLE OF LEUPRORELINE ACETATE DEPOT (LUCRIN DEPOT®) FORMULATIONS IN THE TREATMENT OF PROSTATE CANCER
by: M. I. Volkova
Published: (2014-07-01)

Supplier-dependent differences in intermittent voluntary alcohol intake and response to naltrexone in Wistar rats
by: Shima eMomeni, et al.
Published: (2015-11-01)

Naltrexone‐induced drug eruption
by: Johannes Heck, et al.
Published: (2020-10-01)

Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects
by: Li G, et al.
Published: (2018-12-01)

Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers
by: Kim H, et al.
Published: (2018-04-01)

Theta burst stimulation in adolescent depression: An open-label evaluation of safety, tolerability, and efficacy
by: Siddhesh Sanjeev Shere, et al.
Published: (2021-07-01)

Pharmacokinetics, Safety, and Tolerability of Solifenacin in Patients With Renal Insufficiency
by: Ronald A. Smulders, et al.
Published: (2007-01-01)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
by: Satish Dayal, et al.
Published: (2021-04-01)

Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT
by: John Strang, et al.
Published: (2019-01-01)

MICRONEEDLE-ASSISTED TRANSDERMAL DELIVERY OF NALTREXONE SPECIES: <em>IN VITRO</em> PERMEATION AND <em>IN VIVO</em> PHARMACOKINETIC STUDIES
by: Milewski, Mikolaj
Published: (2011)

Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy.
by: Pedro Gonzales, et al.
Published: (2020-01-01)

Naltrexone Initiation in the Inpatient Setting for Alcohol Use Disorder: A Systematic Review of Clinical Outcomes
by: Robert W. Kirchoff, MD, et al.
Published: (2021-04-01)

Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol
by: Jennifer M. Mitchell, et al.
Published: (2009-01-01)

Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
by: Chaoying Hu, et al.
Published: (2015-01-01)

Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes
by: Patricia J. McLaughlin, et al.
Published: (2019-01-01)

Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil
by: Robert Roscigno, et al.
Published: (2020-11-01)

Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study
by: Jing Zhang, et al.
Published: (2020-01-01)

Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
by: Nathalie M Goemans, et al.
Published: (2016-01-01)

An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch
by: Zhang C, et al.
Published: (2017-03-01)

The Efficacy, Safety, and Tolerability of Probiotics on Depression: Clinical Results From an Open-Label Pilot Study
by: Caroline J. K. Wallace, et al.
Published: (2021-02-01)

Simultaneous determination of naltrexone and bupropion in their co-formulated tablet utilizing green chromatographic approach with application to human urine
by: Sherif A. Abdel-Gawad, et al.
Published: (2018-02-01)

Epidemiologic and Molecular Pathophysiology of Chronic Opioid Dependence and the Place of Naltrexone Extended-Release Formulations in its Clinical Management
by: Albert Stuart Reece
Published: (2012-01-01)

Epidemiologic and Molecular Pathophysiology of Chronic Opioid Dependence and the Place of Naltrexone Extended-Release Formulations in its Clinical Management
by: Albert Stuart Reece
Published: (2012-09-01)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
by: Ishani Landry, et al.
Published: (2021-04-01)